cytochrome c oxidase subunit IIGenealiases: COII · MTCO2
Q-omics provides the consensus-scored MT-CO2 profile across patient tissues and cancer cell-line models. MT-CO2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT-CO2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MT-CO2 protein abundance shows 22,389 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where MT-CO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-CO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-CO2 survival associations across molecular data types. MT-CO2 RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-CO2 RNA expression–survival associations across cancer types. High MT-CO2 expression shows unfavorable associations in SKCM, KIRC and BRCA, but favorable associations in ACC, PAAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MT-CO2 RNA expression.
This table summarizes MT-CO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT-CO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-CO2 shows lower tumor expression in KIRC and LIHC and higher tumor expression in THCA, KICH, READ and PRAD. The KIRC box plot shows higher MT-CO2 RNA expression in normal versus tumor tissue (log2 FC = −0.970, t-test p < 0.001).
This table shows molecular features associated with MT-CO2 in patient tissues and cancer cell lines. In patient samples, MT-CO2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MT-CO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
